Detection of Circulating Tumor DNA Through Liquid Biopsies in Ovarian Cancer Patients and Evaluation of Prognostic and Predictive Values of Circulating Tumor DNA Assay.

Plain-language summary

This study evaluates the detection of circulating tumor DNA from blood samples (liquid biopsy) in ovarian cancer patients and the value of this test in predicting the course of the disease. It enrolled women over 19 with epithelial ovarian cancer and elevated CA-125 levels. It was a study without a phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Yonsei University

Start date

9/10/2019

Estimated completion

6/30/2022

Countries

South Korea

Related genes

Locations

• Seoul, South Korea

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Female, over 19 years of age;
2. Patients with epithelial ovarian cancer
3. Patients with Serum CA-125 \>35 U/mL

Exclusion Criteria:

1. Patients in pregnancy
2. Patients being treated for cancer of other organs, including gynecological cancer.
3. Patients who has difficulty reading and understanding Korean.
4. The tester's determination that the patient will not be able to comply with the clinical trial procedures.
5. Patients with severe infections or other serious medical problems that have resulted in impairment of the patient's function, making it difficult to the trial.